JP2012509659A5 - - Google Patents

Download PDF

Info

Publication number
JP2012509659A5
JP2012509659A5 JP2011536895A JP2011536895A JP2012509659A5 JP 2012509659 A5 JP2012509659 A5 JP 2012509659A5 JP 2011536895 A JP2011536895 A JP 2011536895A JP 2011536895 A JP2011536895 A JP 2011536895A JP 2012509659 A5 JP2012509659 A5 JP 2012509659A5
Authority
JP
Japan
Prior art keywords
chain
tcr
nucleic acid
encoding
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011536895A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509659A (ja
JP6069755B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/065705 external-priority patent/WO2010058023A1/en
Publication of JP2012509659A publication Critical patent/JP2012509659A/ja
Publication of JP2012509659A5 publication Critical patent/JP2012509659A5/ja
Application granted granted Critical
Publication of JP6069755B2 publication Critical patent/JP6069755B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011536895A 2008-11-24 2009-11-24 高親和性t細胞受容体およびその用途 Active JP6069755B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08020396 2008-11-24
EP08020396.1 2008-11-24
PCT/EP2009/065705 WO2010058023A1 (en) 2008-11-24 2009-11-24 High affinity t cell receptor and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015125543A Division JP2015211682A (ja) 2008-11-24 2015-06-23 高親和性t細胞受容体およびその用途

Publications (3)

Publication Number Publication Date
JP2012509659A JP2012509659A (ja) 2012-04-26
JP2012509659A5 true JP2012509659A5 (https=) 2012-12-27
JP6069755B2 JP6069755B2 (ja) 2017-02-01

Family

ID=40521958

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011536895A Active JP6069755B2 (ja) 2008-11-24 2009-11-24 高親和性t細胞受容体およびその用途
JP2015125543A Withdrawn JP2015211682A (ja) 2008-11-24 2015-06-23 高親和性t細胞受容体およびその用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015125543A Withdrawn JP2015211682A (ja) 2008-11-24 2015-06-23 高親和性t細胞受容体およびその用途

Country Status (9)

Country Link
US (4) US8697854B2 (https=)
EP (1) EP2352756B1 (https=)
JP (2) JP6069755B2 (https=)
CN (1) CN102272153B (https=)
AU (1) AU2009317161B2 (https=)
CA (1) CA2743669C (https=)
DK (1) DK2352756T3 (https=)
ES (1) ES2394180T3 (https=)
WO (1) WO2010058023A1 (https=)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
IL296832A (en) 2005-10-18 2022-11-01 Nat Jewish Health Process of preparing red blood cells using conditionally immortalized long-term hematopoietic stem cells and erythropoietin
SG10201803982TA (en) 2008-05-16 2018-07-30 Taiga Biotechnologies Inc Antibodies and processes for preparing the same
DK3339321T3 (da) 2008-08-28 2021-06-21 Taiga Biotechnologies Inc Modulatorer af myc, fremgangsmåder til anvendelse af samme og fremgangsmåder til at identificere stoffer der modulerer myc
DK2352756T3 (da) * 2008-11-24 2012-12-03 Helmholtz Zentrum Muenchen Højaffin T-cellereceptor og anvendelse af denne
WO2010089412A1 (en) * 2009-02-09 2010-08-12 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
CN104334741B (zh) 2012-03-28 2018-08-17 歌德塔有限公司 组合的γ9δ2T细胞受体链交换
EP2844743B1 (en) 2012-05-03 2021-01-13 Fred Hutchinson Cancer Research Center Enhanced affinity t cell receptors and methods for making the same
WO2013169691A1 (en) 2012-05-07 2013-11-14 Trustees Of Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
US9789135B2 (en) 2012-07-20 2017-10-17 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
GB201309421D0 (en) * 2013-05-24 2013-07-10 Imp Innovations Ltd Polypeptides
AU2014301777B2 (en) * 2013-06-26 2017-03-30 Xlifesc, Ltd. High-stability T-cell receptor and preparation method and application thereof
KR102415259B1 (ko) * 2013-11-22 2022-06-30 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 조작된 고-친화도의 인간 t 세포 수용체
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
WO2015113140A1 (en) * 2014-01-29 2015-08-06 University Health Network Methods and compositions for producing a cell expressing a t cell receptor
JP2017507950A (ja) * 2014-02-27 2017-03-23 リセラ・コーポレイションLycera Corporation レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
ES2841274T3 (es) 2014-08-04 2021-07-07 Hutchinson Fred Cancer Res Inmunoterapia con células T específica para WT-1
EP3212774A4 (en) * 2014-10-31 2018-04-11 Baylor College of Medicine Survivin specific t-cell receptor targeting tumor but not t cells
JP6718444B2 (ja) * 2014-11-03 2020-07-08 アカデミッシュ ザイケンホイス レイデン (エイチ.オー.ディー.エヌ. エルユーエムシー) Bob1に対して指向されるT細胞レセプターおよびその使用
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
US10421751B2 (en) 2015-05-05 2019-09-24 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
WO2016187459A1 (en) 2015-05-20 2016-11-24 The Regents Of The University Of California Method for generating human dendritic cells for immunotherapy
MX2017015149A (es) * 2015-05-26 2018-03-28 Advaxis Inc Inmunoterapia personalizada basada en vectores de suministro y usos de esta.
AU2016276947A1 (en) 2015-06-11 2017-12-14 Lycera Corporation Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
WO2016205749A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
JP2018526007A (ja) * 2015-09-04 2018-09-13 トカジェン インコーポレーテッド 2aペプチドを含む組換えベクター
US12241053B2 (en) 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
SG11201803419PA (en) * 2015-10-30 2018-05-30 The Regents Of The Universtiy Of California Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
AU2016355178B9 (en) 2015-11-19 2019-05-30 Massachusetts Institute Of Technology Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
WO2017139405A1 (en) * 2016-02-08 2017-08-17 The General Hospital Corporation Method of reducing tolerization of t cells to tumor antigens
TWI795133B (zh) 2016-04-01 2023-03-01 美商凱特製藥公司 Bcma結合分子類及彼等之用途
CA3019650C (en) 2016-04-01 2023-07-25 Kite Pharma, Inc. Chimeric receptors and methods of use thereof
ES2891578T3 (es) 2016-04-01 2022-01-28 Kite Pharma Inc Antígeno quimérico y receptores de células T y métodos de uso
EP3443123B1 (en) * 2016-04-11 2021-08-11 Board of Regents, The University of Texas System Methods and compositions for detecting single t cell receptor affinity and sequence
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
EP4099015A1 (en) * 2016-06-10 2022-12-07 Gadeta B.V. Novel method for identifying deltat-cell (or gammat-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective response
WO2018035364A1 (en) 2016-08-17 2018-02-22 The Broad Institute Inc. Product and methods useful for modulating and evaluating immune responses
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
US12499971B2 (en) 2016-09-28 2025-12-16 The Broad Institute, Inc. Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
WO2018089386A1 (en) 2016-11-11 2018-05-17 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
EP3548425B1 (en) 2016-12-02 2023-03-29 Taiga Biotechnologies, Inc. Nanoparticle formulations
KR20240007775A (ko) * 2016-12-08 2024-01-16 이매틱스 바이오테크놀로지스 게엠베하 T 세포 수용체 및 이를 사용하는 면역 요법
WO2018129199A1 (en) 2017-01-04 2018-07-12 Nova Southeastern University Natural killer (nk) cells expressing an antigen-specific functional t cell receptor (tcr) complex, methods for production thereof, and methods for therapeutic use thereof
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US11965892B2 (en) 2017-02-12 2024-04-23 Biontech Us Inc. HLA-based methods and compositions and uses thereof
US11963966B2 (en) 2017-03-31 2024-04-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
WO2018183921A1 (en) 2017-04-01 2018-10-04 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
EP3610266A4 (en) 2017-04-12 2021-04-21 Massachusetts Eye and Ear Infirmary TUMOR SIGNATURE OF METASTASIS, COMPOSITIONS OF SUBSTANCES AND USES THEREOF
US12590288B2 (en) 2017-04-12 2026-03-31 The Broad Institute, Inc. Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response
MX2019012398A (es) 2017-04-18 2020-09-25 Broad Inst Inc Composiciones para detectar secreciones y metodos de uso.
EP3622092A4 (en) 2017-05-11 2021-06-23 The Broad Institute, Inc. METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
WO2018213726A1 (en) 2017-05-18 2018-11-22 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
EP3624823A1 (en) 2017-05-18 2020-03-25 UMC Utrecht Holding B.V. Compositions and methods for cell targeting therapies
ES3000510T3 (en) 2017-06-09 2025-02-28 Providence Health & Services Oregon Tumor-infiltrating t-cells for use in the treatment of cancer
WO2018232195A1 (en) 2017-06-14 2018-12-20 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
ES2905757T3 (es) 2017-08-03 2022-04-12 Taiga Biotechnologies Inc Métodos y composiciones para el tratamiento del melanoma
US20200363414A1 (en) * 2017-09-05 2020-11-19 Gritstone Oncology, Inc. Neoantigen Identification for T-Cell Therapy
AU2018338318B2 (en) 2017-09-21 2022-12-22 Massachusetts Institute Of Technology Systems, methods, and compositions for targeted nucleic acid editing
WO2019070755A1 (en) 2017-10-02 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS
WO2019084055A1 (en) 2017-10-23 2019-05-02 Massachusetts Institute Of Technology CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
WO2019094955A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
EP3714041A1 (en) 2017-11-22 2020-09-30 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
CA3095757A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating glioblastomas
CA3096202A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
WO2020041384A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. 3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
US20210324357A1 (en) 2018-08-20 2021-10-21 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
WO2020068304A2 (en) 2018-08-20 2020-04-02 The Broad Institute, Inc. Inhibitors of rna-guided nuclease target binding and uses thereof
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20210379057A1 (en) 2018-10-16 2021-12-09 Massachusetts Institute Of Technology Nutlin-3a for use in treating a mycobacterium tuberculosis infection
US20220170097A1 (en) 2018-10-29 2022-06-02 The Broad Institute, Inc. Car t cell transcriptional atlas
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
JP2022514574A (ja) * 2018-12-18 2022-02-14 エムビーエル インターナショナル コーポレイション pMHC占有率のストレプトアビジン-オリゴコンジュゲート組成物
KR20240091046A (ko) 2018-12-21 2024-06-21 바이오엔테크 유에스 인크. Hla 클래스 ii-특이적 에피토프 예측 및 cd4+ t 세포 특징화를 위한 방법 및 시스템
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
WO2020180733A1 (en) 2019-03-01 2020-09-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
EP3942023A1 (en) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
MX2021011462A (es) 2019-03-25 2021-12-15 Univ Health Network Receptores de linfocitos t y metodos de uso de los mismos.
CN113874033A (zh) 2019-04-08 2021-12-31 泰加生物工艺学公司 用于冷冻保存免疫细胞的组合物和方法
EP3969041A4 (en) 2019-05-14 2023-05-10 Taiga Biotechnologies, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
US20220226464A1 (en) 2019-05-28 2022-07-21 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
CN110357953B (zh) * 2019-07-17 2022-05-03 深圳市因诺转化医学研究院 识别人巨细胞病毒pp65抗原的TCR
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
US12195723B2 (en) 2019-11-08 2025-01-14 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
US11865168B2 (en) 2019-12-30 2024-01-09 Massachusetts Institute Of Technology Compositions and methods for treating bacterial infections
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
WO2021173756A1 (en) * 2020-02-27 2021-09-02 Board Of Regents, The University Of Texas System Engineered t cell receptors and methods of use
US20230405046A1 (en) * 2020-03-16 2023-12-21 Biontech Cell & Gene Therapies Gmbh Antigen-specific t cell receptors and t cell epitopes
CN115397863A (zh) 2020-04-01 2022-11-25 基因医疗免疫疗法有限责任公司 Cd3融合蛋白及其用途
AU2021276264A1 (en) * 2020-05-18 2022-12-22 Board Of Regents, The University Of Texas System Engineered T cell receptors and methods of use
WO2022187280A1 (en) 2021-03-01 2022-09-09 Dana-Farber Cancer Institute, Inc. Personalized redirection and reprogramming of t cells for precise targeting of tumors
US20240277842A1 (en) 2021-06-07 2024-08-22 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
CN113929767B (zh) * 2021-10-14 2023-11-24 深圳大学总医院 具有高亲和力的t细胞受体及其用途
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024192141A1 (en) 2023-03-13 2024-09-19 Dana-Farber Cancer Institute, Inc. Treatment of cancers having a drug-resistant mesenchymal cell state
WO2024226838A2 (en) 2023-04-25 2024-10-31 The Brigham And Women's Hospital, Inc. Treatment of autoimmune diseases having a pathogenic t cell state
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415553A (en) 1973-08-06 1983-11-15 Dso "Pharmachim" Compositions, processes for their preparation and method for treatment of neoplasms
US4568542A (en) 1981-06-09 1986-02-04 Lee Biomolecular Research Laboratories, Inc. Vaccine compositions
JPH0751511B2 (ja) 1982-03-15 1995-06-05 味の素株式会社 インターロイキン2を含有してなる癌治療剤
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US5582831A (en) 1991-11-26 1996-12-10 Yeda Research And Development Co., Ltd. Anti-tumor vaccines
US5156841A (en) 1988-08-26 1992-10-20 United States Of America Anti-tumor vaccine
US5290551A (en) 1990-05-08 1994-03-01 Thomas Jefferson University Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten
US6077519A (en) 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
WO1996004314A1 (en) 1994-07-29 1996-02-15 Dade International, Inc. Mhc complexes and uses thereof
US6143292A (en) 1995-05-25 2000-11-07 Baxter International Inc. Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
CA2246333A1 (en) * 1996-03-05 1997-09-12 The Scripps Research Institute Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6458585B1 (en) 1996-08-14 2002-10-01 Nexell Therapeutics Inc. Cytokine-free culture of dendritic cells
US6063375A (en) 1996-09-10 2000-05-16 Medical University Of South Carolina Semiallogeneic cell hybrids and related methods for treating cancer
CA2278678A1 (en) 1997-01-31 1998-08-06 Research Corporation Technologies, Inc. Cancer immunotherapy with semi-allogeneic cells
AU7983198A (en) 1997-06-23 1999-01-04 Ludwig Institute For Cancer Research Improved methods for inducing an immune response
EP1005531A2 (en) 1997-07-21 2000-06-07 Cerus Corporation Method of treating leukocytes, leukocyte compositions and methods of use thereof
WO2000076537A2 (en) 1997-09-10 2000-12-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of semi-allogeneic cell line-peptide complexes for the treatment of cancer, aids and other viral diseases
WO2001036680A2 (en) 1999-11-16 2001-05-25 Eastman Eric M METHODS OF PREPARING cRNA
US20020123479A1 (en) 1999-12-08 2002-09-05 Song Elizabeth S. Immunostimulation mediated by gene-modified dendritic cells
AU2002225990B2 (en) 2000-10-20 2007-07-19 Tsuneya Ohno Fusion cells and cytokine compositions for treatment of disease
EP1201760A1 (en) 2000-10-30 2002-05-02 ARTEMIS Pharmaceuticals GmbH Influenza virus vector for human dendritic cells
WO2002072796A2 (en) 2001-03-12 2002-09-19 Cellcure Aps Continuous, normal human t-lymphocyte cell lines comprising a recombinant immune receptor with defined antigen specificity
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
DE10132502A1 (de) 2001-07-05 2003-01-23 Gsf Forschungszentrum Umwelt Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
ATE328279T1 (de) 2002-08-23 2006-06-15 Deutsches Rheuma Forschungszen Verfahren zum nachweis und zur isolierung von t- lymphozyten, die ein definiertes antigen erkennen
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
EP1814580B1 (en) 2004-11-24 2016-08-10 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
DK1910521T3 (da) * 2005-08-05 2011-02-07 Helmholtz Zentrum Muenchen Generering af allo-begrænsede, antigenspecifikke T-celler
EP1795599A1 (en) 2005-12-09 2007-06-13 Schuler, Gerold, Prof. Dr. Methods for generating antigen-specific effector T cells
CA2651174A1 (en) 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
EP1870418A1 (en) 2006-06-20 2007-12-26 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Allorestricted peptide-specific T cells
EP1878744A1 (en) 2006-07-13 2008-01-16 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them
US8088379B2 (en) 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
EP1932537A1 (en) 2006-12-12 2008-06-18 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Expression of transgenic T cell receptors in LAK-T cells
JP5292550B2 (ja) * 2007-03-23 2013-09-18 静岡県 T細胞レセプターβ鎖遺伝子及びα鎖遺伝子
EP2144935A2 (en) * 2007-03-29 2010-01-20 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
WO2010012829A1 (en) 2008-07-31 2010-02-04 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Her2/neu specific t cell receptors
DK2352756T3 (da) * 2008-11-24 2012-12-03 Helmholtz Zentrum Muenchen Højaffin T-cellereceptor og anvendelse af denne
WO2010089412A1 (en) * 2009-02-09 2010-08-12 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof
EP3212774A4 (en) * 2014-10-31 2018-04-11 Baylor College of Medicine Survivin specific t-cell receptor targeting tumor but not t cells
ES2987442T3 (es) * 2015-05-04 2024-11-14 Theriva Biologics S L Adenovirus oncolíticos con mutaciones en epítopos de adenovirus inmunodominantes y su uso en el tratamiento del cáncer
CN115397863A (zh) * 2020-04-01 2022-11-25 基因医疗免疫疗法有限责任公司 Cd3融合蛋白及其用途

Similar Documents

Publication Publication Date Title
JP2012509659A5 (https=)
ES2609925T3 (es) Proteínas de fusión con LLO no hemolítica y métodos para utilizar las mismas
TWI238853B (en) Tumour-associated antigen derivative from the MAGE family, and the nucleic acid, vector, host cell, vaccine, and preparation thereof
CN107531776B (zh) 用于诊断和治疗癌症的组合物和方法
Balza et al. Targeted Delivery of Tumor Necrosis Factor-α to Tumor Vessels Induces a Therapeutic T Cell–Mediated Immune Response that Protects the Host Against Syngeneic Tumors of Different Histologic Origin
AU2019232729B2 (en) Methods and compositions for treating cancer with ECM-affinity peptides linked to cytokines
CN110835371A (zh) 抗ccr8单克隆抗体及其应用
WO2015184941A1 (zh) 一种cd7纳米抗体、其编码序列及应用
JP2017529059A5 (https=)
JP2020509737A5 (https=)
DK2567983T3 (en) A TUMOR-TARGETING TNF-RELATED apoptosis inducing LIGANDVARIANT AND USE THEREOF
EP3480212B1 (en) Il13ralpha2 peptide and its uses
Ziffels et al. Antibody-based delivery of cytokine payloads to carbonic anhydrase IX leads to cancer cures in immunocompetent tumor-bearing mice
ES2316191T3 (es) Nueva proteina antigenica tumoral sart-3 y peptido antigenico tumoral de la misma.
WO2023179789A1 (zh) 干扰趋化素样因子超家族成员6(cmtm6)表达的基因治疗载体的制备和抗肿瘤应用
CN121013863A (zh) Tnfr2结合多肽及使用方法
KR102166549B1 (ko) 혈뇌장벽 투과성 펩티드 및 이를 포함하는 컨쥬게이트
AU766898B2 (en) Tumor associated antigen 791Tgp72
AU2019282316B2 (en) Compositions and methods for diagnosis and treatment of cancer
JP2024532602A (ja) 天然分子に近いポリペプチド融合分子
Koumarianou et al. Development of a novel bi-specific monoclonal antibody approach for tumour targeting
CN101623503A (zh) 生存素与路易斯寡糖的复合物及其制备方法和应用
KR20200038942A (ko) 약학적 키트 및 그의 용도
AU2005221207B2 (en) Therapeutic use of RM1antigen
JP4473730B2 (ja) 過剰増殖性細胞を認識する抗体ならびにその作製および使用方法